Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Anlotinib in Perioperative NSCLC
NCT05460195Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05460195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460195.